In today’s briefing:
- Hansoh Pharmaceutical (3692 HK): Strengthening Innovative Portfolio Through In-Licensing
- Wuxi Biologics (2269.HK) 2022H1 – Hard to Achieve V-Share Rebound
- More Companies Are Hiring Women Directors, but to Solve the Fundamental Problem of Diversity
Hansoh Pharmaceutical (3692 HK): Strengthening Innovative Portfolio Through In-Licensing
- Hansoh Pharmaceutical (3692 HK) is strengthening its innovative drug pipeline. In August the company in-licensed one clinical stage drug candidate for women health, having large addressable market opportunity in China.
- Earlier in May, entered into an exclusive license agreement with NiKang Therapeutics and obtained an exclusive license to develop and commercialize NKT2152 for the treatment of cancer within China.
- Hansoh’s self-developed oncology drug is getting closer to the UK approval through its partner EQRx. The company received approval for one generic oncology drug in China.
Wuxi Biologics (2269.HK) 2022H1 – Hard to Achieve V-Share Rebound
- WuXi Biologics released 2022H1 results. The Company maintained its growth momentum. We highlight some positive sides. However, gross profit margin decreased. Considering the future trend, margin performance is not optimistic.
- A drop in demand has already occurred. Meanwhile, after the biologic drug boom has passed, the “low-hanging fruit” is gone, there could be more magnified cyclical problems for WuXi Biologics.
- As an old generation CXO, it’s difficult for WuXi Biologics to achieve V-shaped rebound or hit new highs.2022 is a good time to offload. Investors can take advantage of it.
More Companies Are Hiring Women Directors, but to Solve the Fundamental Problem of Diversity
- It shows that many companies still do not recognize the importance of diversity and that the hiring of women independent directors is merely a numbers game.
- In Japan, there is the belief that a close-knit organization is more effective in achieving its goals, and there is a practice of excluding different opinions by emphasizing homogeneity.
- In addition to the repeated disregard for women’s rights, the deep-seated problem of accepting this disregard is the reason diversity has not truly progressed.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars